Future studies will address the downstream regulation of these events, such as understanding how the cell cycle is arrested (e.g., through p53 and/or p21 mechanisms), the use of a pan-centromeric probe [72] that will allow for the identification of potential mitotic disruption and errors in chromosome number, understanding any changes in DNA repair, and understanding the events downstream of GJIC dysregulation, such as an imbalance in bioactive lipids (i.e., eicosanoids) leading to potential adverse effects (e.g., cancer and inflammation) [23]. The gene discussed is TP53; the disease is cancer.